|
Toxicology and Safety Pharmacology
Dr. Peter-Jürgen Kramer
Certified Expert in Toxicology GT/DGPT, EUROTOX Registered Toxicologist
- Wide experience as leading toxicologist in the chemical and pharmaceutical industry,
Global Head of Toxicology of Merck KGaA/Merck Serono
- Long-standing lecturer in toxicology at universities in Germany and France
- More than 2 decades official representative of Germany in expert groups of EU and OECD for the harmonisation of toxicological test methods, among others also for a drastic reduction of animal testing
- Repeatedly nominated as member of expert committees (juries) of the German Ministry of Education and Research (BMBF), granting of public funding for research projects in the fields of 'Replacement of Animal Testing' and 'Innovation in Drug Development'.
Activities 2009/2010/2011
- Active involvement in the development and shaping of toxicology in Germany and Europe (Drug and Chemical Safety)
- Member of Corporate Sub-Committee of the Federation of European Toxicologists & European Societies of Toxicology (EUROTOX)
- Member of Scientific Programme Committee and Local Organizing Committee of 46th Congress of the European Societies of Toxicology in Dresden, EUROTOX 2009
13-16 September 2009 in Dresden, Germany
- Vice-President of the German Society of Toxicology (GT), 2003 - 2010
- Member of the Weiterbildungskommission (Formation: certified Expert in Toxicology (GT/DGPT)
- Member of the Beratungskommission of the German Society of Toxicology(GT)
- Member of the Editorial Board of the journal ‘Archives of Toxicology’
- Member of the Expertengremium für Chemikaliensicherheit (Expert Committee for Chemical Safety)
- Member of Board of Trustees of Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany, 2000 - 2009
- Conduct of seminars in the fields of preclinical development of drugs (e.g. Preclinical Drug Safety - Forum Institute, Heidelberg)
- Member of US Society of Toxicology (SOT) and Drug Information Association (DIA)
- Consulting for smaller companies
- Lecturship at the Universities of Darmstadt, Bonn and Lyon
Subjects: Toxicological Testing, Assessment of Toxicology Results, General Toxicology, Genetic Toxicology, Reproduction Toxicology
Publications (Selection)
- Are chromosomal aberration tests in vitro particulary prone to artificial findings?
P.-J. Kramer, bga Schriften 1/1993
- Neurotoxicity Risk Assessment of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) as a Synthetic Impurity od Drugs
Kramer, P.-J.; Caldwell, J.; Hofmann, A.; Tempel, P.; Weiße, G., Human & Experimental Toxicology 17:283-293 (1998)
- Genetic Toxicology
Kramer, P.-J., J. Pharm. Pharmacol. 50:395-405 (1998)
- The polycyclic musk 7-acetyl-1,1,3,4,4,6-hexamethyl-1,2,3,4,-tetrahydronaphthaline lacks tumor initiating and promoting activity in rats exposed to human-relevant doses.
P. Steinberg, I. Zschaler, E. Thom, M. Kuna, G. Wüst, A. Schäfer-Schwebel, R. Müller, P.-J. Kramer, G. Weiße, Arch. Toxicol. 75:562-568 (2001)
- Zur Bedeutung von genetischen Polymorphismen von Fremdstoff-metabolisierenden Enzymen in der Toxikologie. Stellungnahme der Beratungskommission der Sektion Toxikologie der Deutschen Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie (DGPT)
THOMAS SCHULZ, GISELA DEGEN, HEIDI FOTH, REGINE KAHL, PETER-JÜRGEN KRAMER, WERNER LILIENBLUM, DIETER SCHRENK, HERMANN SCHWEINFURTH, Umweltmed Forsch Prax 7 (4) 7A (2002)
- The REACH concept and its impact on toxicological sciences.
J.G. Hengstler, H. Foth, R. Kahl, P.-J. Kramer, W. Lilienblum, T. Schulz, H. Schweinfurth, Toxicology 220:232-239 (2006)
- Nadine Zidek, Juergen Hellmann, Peter-Juergen Kramer and Philip Hewitt, Acute Hepatotoxicity: A predictive Model based on Focused Illumina Microarrays,Toxicological Sciences 99(1): 289-302 (2007)
- Non-clinical Study Reports (Module 4 EU-CTD) Guide to Drug Regulatory Affairs
Klaus Olejniczak, Gerd Bode, Peter Kasper, Eckhard von Keutz, Peter-Jürgen Kramer, Editio Cantor 685-716 (2007)
- Hengstler JG, Foth H, Gebel T, Kramer PJ, Lilienblum W, Schweinfurth H, Völkel W, Wollin K-M, Gundert-Remy U. Critical evaluation of key evidence on the human health hazards of exposure to bisphenol A. Crit Rev Toxicol. 2011 Apr;41(4):263-91.
Fraunhofer Institute for Toxicology and Experimental Medicine
-
Research for human health is the focus of the Fraunhofer ITEM. We assess the risks of potentially harmful substances, investigate mechanisms of action and support our clients in the development of new medications. The most important target organs of our research are the lungs and airways.
More about us
News
-
Fraunhofer ITEM is participating in two German centers for health research
The Fraunhofer Institute for Toxicology and Experimental Medicine will participate in two German centers for health research: the German center for pulmonary research and the German center for infection research.
-
Nanomaterials being put to the test
Press release dated September 2, 2010
With 1.25 million euros the German Federal Ministry of Education and Research is funding the "CarboTox“ research alliance, in which the Fraunhofer ITEM is playing a key role. Over the next three years, the potential risks of carbon nanotubes will be investigated.
-
How dangerous are carbon nanoparticles
Press release dated August 10, 2010
With an amount of 2.5 million euros the German Federal Ministry for Education and Research is funding the carbon black research alliance, in which the Fraunhofer ITEM is also participating. Over the next three years, the toxicological effects of carbon black nanoparticles on the lungs and airways will be tested here.
-
New brochure on nanotechnology research
What are the opportunities and the potential of nanotechnology? The Fraunhofer ITEM and five other institutes of the Fraunhofer Group for Life Sciences are doing research in this promising area. Their projects and topics are described in the new brochure "Nanotechnology research for man and the environment".
-
Fraunhofer ITEM receives regulatory approval to manufacture investigational drugs
Press release dated April 30,2010 In April 2010, the Fraunhofer ITEM received regulatory approval for aseptic manufacturing of clinical investigational drug products. In addition to performing pre-clinical investigations in compliance with GLP (Good Laboratory Practice) and clinical trials of different phases according to GCP (Good Clinical Practice), the Fraunhofer ITEM is now also in a position to manufacture clinical investigational drug products for administration by infusion in compliance with the Good Manufacturing Practice (GMP) guidelines in a study-specific manner and for each patient individually.

The new News Report October 2010 is available: download PDF file
|
Set Bookmark